GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharming Group (NAS:PHAR) » Definitions » Short-Term Debt

PHAR (Pharming Group) Short-Term Debt : $4.6 Mil (As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is Pharming Group Short-Term Debt?

Pharming Group's Short-Term Debt for the quarter that ended in Mar. 2025 was $4.6 Mil.

Pharming Group's quarterly Short-Term Debt increased from Sep. 2024 ($3.3 Mil) to Dec. 2024 ($4.2 Mil) and increased from Dec. 2024 ($4.2 Mil) to Mar. 2025 ($4.6 Mil).

Pharming Group's annual Short-Term Debt increased from Dec. 2022 ($1.8 Mil) to Dec. 2023 ($1.8 Mil) and increased from Dec. 2023 ($1.8 Mil) to Dec. 2024 ($4.2 Mil).

Pharming Group Short-Term Debt Historical Data

The historical data trend for Pharming Group's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharming Group Short-Term Debt Chart

Pharming Group Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.04 1.88 1.77 1.82 4.25

Pharming Group Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 134.89 3.15 3.32 4.25 4.56

Pharming Group Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Pharming Group Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Pharming Group's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharming Group Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharming Group (NAS:PHAR) » Definitions » Short-Term Debt
Comparable Companies
XAMS:VVY XAMS:GLPG VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX SMMT RPRX OCSE:GMAB XKRX:196170 INCY HKSE:02269 INSM HKSE:01801
Traded in Other Exchanges
PHGUF:USA PHARM:Netherlands PHARMa:UK 0QCO:UK PHGN:Germany
Address
Darwinweg 24, Leiden, ZH, NLD, 2333 CR
Website
https://www.pharming.com
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.